Quantcast
Last updated on April 20, 2014 at 17:20 EDT

Liver Cancer Therapeutics Market to 2018

July 8, 2013

DUBLIN, July 8, 2013 /PRNewswire/ –

Research and Markets (
http://www.researchandmarkets.com/research/b2njt5/liver_cancer) has announced the
addition of the “Liver Cancer Therapeutics Market to 2018 – Nexavar, the Only Approved
Targeted Therapy for Advanced Disease, Continues to Dominate as Other Late Stage Trials
Fail” [http://www.researchandmarkets.com/research/b2njt5/liver_cancer ] report to their
offering.

(Logo:
http://photos.prnewswire.com/prnh/20130307/600769 )

Leading business intelligence provider, GBI Research, has released its latest research
report, entitled: Liver Cancer Therapeutics Market to 2018 – Nexavar, the Only Approved
Targeted Therapy for Advanced Disease, Continues to Dominate as Other Late Stage Trials
Fail.

The report provides insights into the liver cancer therapeutics market in the US, the
top five European countries (the UK, Germany, France, Italy and Spain) and Japan, with
market forecasts until 2018. It provides in-depth analysis of the major marketed products,
as well as insights into the liver cancer therapeutics R&D pipeline. The report also gives
in-depth analysis of the unmet needs, drivers and barriers that affect the markets in
these countries. Additionally, it discusses the global pipeline for all the liver cancer
molecules across various stages of development.

The report is built using data and information sourced from proprietary databases,
primary and secondary research and in-house analysis by GBI Research’s team of industry
experts.

GBI Research found that the liver cancer therapeutics in the top seven markets (the
US, the UK, Germany, France, Spain, Italy and Japan) was estimated at $374.3m in 2011,
having grown at a Compound Annual Growth Rate (CAGR) of 21.7% from 2004. Growth was driven
by an increase in the patient volume and the Annual Cost of Therapy (ACT) per patient,
which increased due to the approval of Nexavar (sorafenib) in the US and Europe. The
market is forecast to reach revenues of $644.3m by 2018, growing at a CAGR of 8.1% from
2011.

The current competition in the liver cancer market
[http://www.researchandmarkets.com/research/b2njt5/liver_cancer ] is weak, as Nexavar is
the only drug approved for advanced Hepatocellular Carcinoma (HCC) with the exception of
Miripla (miriplatin) in Japan. However, there are some molecules in Phase III development
as first-line and second-line treatments which promise to influence the competitive
landscape in the next two to three years. The anticipated launch of Eli Lilly’s
ramucirumab (IMC-1121B), a monoclonal antibody in 2014; Celsion Corporation’s ThermoDox in
2014; and PrevOnco in 2015 will drive the market forward.

Companies Mentioned

        - Bayer
        - Dainippon Sumitomo Pharma

For more information visit

http://www.researchandmarkets.com/research/b2njt5/liver_cancer

        Research and Markets
        Laura Wood, Senior Manager.
        press@researchandmarkets.com
        U.S. Fax: +1-646-607-1907
        Fax (outside U.S.): +353-1-481-1716
        Sector: Oncology
         [http://www.researchandmarkets.com/categories.asp?cat_id=122&campaign_id=b2njt5 ]


    Photo: 

http://photos.prnewswire.com/prnh/20130307/600769

SOURCE Research and Markets


Source: PR Newswire